Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies

Clarivate's 2025 Drugs to Watch Report:
The report identifies 11 drugs expected to achieve blockbuster status or significantly alter treatment paradigms by 203023.

Novo Nordisk's Contributions:

AWIQLI (LAI 287; insulin icodec):
A once-weekly, subcutaneous insulin for type 1 and type 2 diabetes mellitus, already marketed in several countries3.

CagriSema (cagrilintide + semaglutide):
A next-generation GLP-1 therapy combining amylin and GLP-1 receptor agonists for obesity and type 2 diabetes, potentially offering superior efficacy over existing treatments3.

Eli Lilly's Contributions:

Orforglipron (GLP-1):
An oral anti-obesity medication (AOM) expected to launch, possibly alongside oral semaglutide, marking a significant development in obesity treatment5.

Key Therapeutic Trends:

Radiopharmaceutical Theranostics:
Redefining cancer treatment with a "see it and treat it" paradigm3.

Gene Editing Technologies:
Expected to innovate personalized medicine in 20253.

AI and Machine Learning:
Enhancing drug discovery and development, with a focus on precision oncology and addressing global health disparities34.

Regulatory Innovations:

Real-World Data (RWD):
Increasingly used to improve regulatory submissions and emphasize patient-reported outcomes and health equity3.

Sources:

2. https://www.gurufocus.com/news/2649484/clarivate-plc-unveils-2025-drugs-to-watch-report-highlighting-transformative-therapies

3. https://www.europeanpharmaceuticalreview.com/article/242863/potential-blockbuster-drugs-to-watch-in-2025/

4. https://clarivate.com/coming-soon-drugs-to-watch-2025/

5. https://www.iqvia.com/locations/emea/blogs/2025/01/outlook-for-obesity-in-2025-more-than-a-transition-year